Numares Health: Receives Up To €20M from European Investment Bank

Numares Health Receives Up To €20M from European Investment Bank

• Numares Health AG, a Regensburg, Germany-based provider of a fully automated in-vitro diagnostics platform, received up to €40m in funding
• The European Investment Bank provided un up to €20m quasi equity financing for further research and development
• Existing investors will contribute a complementary €20m for marketing investments to achieve mass commercialization of the proprietary technology products in the EU and U.S.
• NumaresHealth analyzes biomarker constellations with advanced use of nuclear magnetic resonance and artificial intelligence to improve diagnostics
• The company has developed a fully automated in-vitro diagnostics platform, the AXINON System, which aims to improve the quality of diagnosing chronic diseases of the kidney, heart and liver, as well as cancer and multiple sclerosis
• The system combines nuclear magnetic resonance (NMR) and artificial intelligence to collect and analyze metabolomic data from blood or urine samples